The efficient priming of E7-specific CD8+ T cells, which is necessary to achieve tumor regression, was made possible by the use of the STxB-vaccine that favors induction of CD8+ T cells [36, 37], in the absence of a marked CD4 activation. Here, CD4 is linked to neoplasm.